Stryker Corp SYK

NYSE · EDGAR · Updated Oct 24, 2026

Stryker Corp (NYSE: SYK) is a medical device company.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Program	Indication	Modality	Stage
Amplitude Vascular Systems intravascular lithotripsy platform (acquired May 2026)	Complex peripheral arterial disease	—	NA_NON_THERAPEUTIC

Jan 1, 2027
n/a Stryker announces Kevin Lobo will transition from CEO to Executive Chair and Spencer Stiles will become CEO effective January 1, 2027.Spencer Stiles, currently President and Chief Operating Officer of Stryker, will succeed Lobo as Chief Executive Officer and will also be appointed as a member of the company's Board at that time. Filing
Jan 1, 2026
n/a Stryker announces CEO succession with Spencer Stiles to succeed Kevin Lobo as CEO effective January 1, 2027.Spencer Stiles, currently President and Chief Operating Officer of Stryker, will succeed Lobo as Chief Executive Officer and will also be appointed as a member of the company's Board at that time. Filing

Cash runway against each catalyst, with the company's own runway statement
Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
Expected move for each dated catalyst, from comparable past events
Phase 2 evidence behind each Phase 3 readout
Companies on the same target or class
Full catalyst list with filing sentences, deals, registered trials, Excel export